Intellia Therapeutics Secures FDA Priority Review for Gene Editing Therapy and Files Shelf Registration
Trendline

Intellia Therapeutics Secures FDA Priority Review for Gene Editing Therapy and Files Shelf Registration

What's Happening? Intellia Therapeutics, a clinical-stage genome editing company, has received FDA priority review for its hereditary angioedema gene editing therapy, lonvo z. The company also reported positive trial data and is advancing its phase 3 programs for ATTR polyneuropathy and cardiomyopat
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.